BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 7692048)

  • 1. Synthesis and biological evaluation of cholecystokinin analogs in which the Asp-Phe-NH2 moiety has been replaced by a 3-amino-7-phenylheptanoic acid or a 3-amino-6-(phenyloxy)hexanoic acid.
    Amblard M; Rodriguez M; Lignon MF; Galas MC; Bernad N; Artis-Noël AM; Hauad L; Laur J; Califano JC; Aumelas A
    J Med Chem; 1993 Oct; 36(20):3021-8. PubMed ID: 7692048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological activities of pseudopeptide analogues of the C-terminal heptapeptide of cholecystokinin. On the importance of the peptide bonds.
    Rodriguez M; Lignon MF; Galas MC; Fulcrand P; Mendre C; Aumelas A; Laur J; Martinez J
    J Med Chem; 1987 Aug; 30(8):1366-73. PubMed ID: 2441054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors.
    Charpentier B; Dor A; Roy P; England P; Pham H; Durieux C; Roques BP
    J Med Chem; 1989 Jun; 32(6):1184-90. PubMed ID: 2724293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholecystokinin increases intracellular Ca2+ concentration in the Human JURKAT T Lymphocyte cell line.
    Lignon MF; Bernad N; Martinez J
    Eur J Pharmacol; 1993 May; 245(3):241-6. PubMed ID: 8335062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A synthetic peptide derivative that is a cholecystokinin receptor antagonist.
    Lignon MF; Galas MC; Rodriguez M; Laur J; Aumelas A; Martinez J
    J Biol Chem; 1987 May; 262(15):7226-31. PubMed ID: 2438274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of peripheral cholecystokinin receptor heterogeneity by cyclic and related linear analogues of CCK26-33: synthesis and biological properties.
    Charpentier B; Durieux C; Menant I; Roques BP
    J Med Chem; 1987 Jun; 30(6):962-8. PubMed ID: 2438407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme-resistant CCK analogs with high affinities for central receptors.
    Charpentier B; Durieux C; Pelaprat D; Dor A; Reibaud M; Blanchard JC; Roques BP
    Peptides; 1988; 9(4):835-41. PubMed ID: 3226959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic CCK8 analogs with antagonist activity on pancreatic receptors: in vivo study in the rat, compared to non-peptidic antagonists.
    Nagain C; Galas MC; Lignon MF; Rodriguez M; Martinez J; Rozé C
    Pancreas; 1991 May; 6(3):275-81. PubMed ID: 1713671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boc-Trp-Orn(Z)-Asp-NH2 and derivatives: a new family of CCK antagonists.
    Gonzalez-Muniz R; Bergeron F; Marseigne I; Durieux C; Roques BP
    J Med Chem; 1990 Dec; 33(12):3199-204. PubMed ID: 1701834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic cholecystokinin analogues with high selectivity for central receptors.
    Charpentier B; Pelaprat D; Durieux C; Dor A; Reibaud M; Blanchard JC; Roques BP
    Proc Natl Acad Sci U S A; 1988 Mar; 85(6):1968-72. PubMed ID: 3162318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between phospholipid breakdown, intracellular calcium mobilization and enzyme secretion in rat pancreatic acini treated with Boc-[Nle28, Nle31]-CCK-7 and JMV180, two cholecystokinin analogues.
    Lignon MF; Galas MC; Rodriguez M; Martinez J
    Cell Signal; 1990; 2(4):339-46. PubMed ID: 1701321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two functionally distinct cholecystokinin receptors show different modes of action on Ca2+ mobilization and phospholipid hydrolysis in isolated rat pancreatic acini. Studies using a new cholecystokinin analog, JMV-180.
    Matozaki T; Göke B; Tsunoda Y; Rodriguez M; Martinez J; Williams JA
    J Biol Chem; 1990 Apr; 265(11):6247-54. PubMed ID: 1690723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [3H]pBC 264, a suitable probe for studying cholecystokinin-B receptors: binding characteristics in rodent brains and comparison with [3H]SNF 8702.
    Durieux C; Ruiz-Gayo M; Corringer PJ; Bergeron F; Ducos B; Roques BP
    Mol Pharmacol; 1992 Jun; 41(6):1089-95. PubMed ID: 1614411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
    Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ
    J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the states and populations of the rat pancreatic cholecystokinin receptor using the full peptide antagonist JMV 179.
    Silvente Poirot S; Hadjiivanova C; Escrieut C; Dufresne M; Martinez J; Vaysse N; Fourmy D
    Eur J Biochem; 1993 Mar; 212(2):529-38. PubMed ID: 8444190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replacement of Tyr-SO3H by a p-carboxymethyl-phenylalanine in a CCK8-derivative preserves its high affinity for CCK-B receptor.
    McCort-Tranchepain I; Ficheux D; Durieux C; Roques BP
    Int J Pept Protein Res; 1992 Jan; 39(1):48-57. PubMed ID: 1378822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pseudopeptide that is a potent cholecystokinin agonist in the peripheral system is able to inhibit the dopamine-like effects of cholecystokinin in the striatum.
    Mendre C; Rodriquez M; Gueudet C; Lignon MF; Galas MC; Laur J; Worms P; Martinez J
    J Biol Chem; 1988 Aug; 263(22):10641-5. PubMed ID: 3392031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
    Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
    J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCK-JMV-180: a peptide that distinguishes high-affinity cholecystokinin receptors from low-affinity cholecystokinin receptors.
    Stark HA; Sharp CM; Sutliff VE; Martinez J; Jensen RT; Gardner JD
    Biochim Biophys Acta; 1989 Feb; 1010(2):145-50. PubMed ID: 2463851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Phenylethyl ester and 2-phenylethyl amide derivative analogues of the C-terminal hepta- and octapeptide of cholecystokinin.
    Fulcrand P; Rodriguez M; Galas MC; Lignon MF; Laur J; Aumelas A; Martinez J
    Int J Pept Protein Res; 1988 Nov; 32(5):384-95. PubMed ID: 2463231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.